# OnCo record ielsg32 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/ielsg32/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "ielsg32", "NCT01011920" ;
  schema:name "IELSG32"@en ;
  schema:alternateName "IELSG-32"@en, "MATRix trial"@en ;
  schema:description "IELSG32 built the MATRix regimen that is now the standard first treatment for lymphoma confined to the brain: adding rituximab and thiotepa to methotrexate and cytarabine doubled the complete remission rate, and its second part showed that a stem cell transplant works as well as whole-brain radiotherapy for consolidation, with less harm to thinking."@en ;
  schema:url <https://onco.cc/trials/ielsg32/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01011920> ;
  onco:status "positive" ;
  onco:tag "soc-trials" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/primary-cns-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/brain-tumours/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/> ;
  onco:drugs <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/cytarabine/>, <https://onco.cc/drugs/thiotepa/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/carmustine/> ;
  onco:institutions <https://onco.cc/institutions/ielsg/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-ielsg32-matrix-induction-ferreri-lancet-haematol-2016/>, <https://onco.cc/key-papers/paper-ielsg32-wbrt-vs-asct-consolidation-ferreri-lancet-haematol-2017/> .